The European Union is learning a possible hyperlink between suicidal ideas and medicines like Ozempic used for weight reduction and to deal with sort 2 diabetes.
The European Medicines Company, an company of the EU, introduced Friday that its security committee is conducting a evaluation of knowledge linking ideas of self-harm and suicide with medicines together with Ozempic, Saxenda, and Wegovy — referred to as GLP-1 receptor agonists.
The company initiated the evaluation after the Icelandic medicines company flagged experiences of a potential hyperlink between the drug and ideas of self-harm or suicide.
Within the official press release, the EMA harassed “It isn’t but clear whether or not the reported instances are linked to the medicines themselves or to the sufferers’ underlying situations or different elements.”
Officers are analyzing about 150 reported potential instances of self-injury and suicidal ideas. The evaluation began on July 3, 2023, and is anticipated to finish in November 2023.
Utilization of those medicines, which include the lively elements semaglutide and liraglutide, skyrocketed lately as celebrities touted them on social media. In April 2023, information confirmed that prescriptions for Ozempic had doubled because the summer time of 2021 to greater than 1.2 million, and Ozempic was listed on the U.S.’s FDA drug scarcity checklist.
The EU press launch indicated that every one the medicines mixed have an publicity of greater than 20 million patient-years up to now. One patient-year is equal to 1 affected person taking one 12 months of the medication, in response to the discharge.
Copyright 2023 Nexstar Media Inc. All rights reserved. This materials will not be printed, broadcast, rewritten, or redistributed.
- EU to check potential hyperlink between Ozempic, suicidal ideas
- Verify all information and articles from the most recent World updates.
- Please Subscribe us at Google News.